A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Exclusion Criteria

• •1. Previous treatment with immune checkpoint inhibitors (PD-1/PD-L1 drugs or drugs acting on another T cell receptor (e.g., CTLA-4 etc.), as well as immune checkpoint agonistic antibodies (e.g., anti ICOS , CD40 , CD137 , GITR , OX40 antibodies, etc.), and immune cell therapy.
• •2. Patients who have received systemic corticosteroids or other immunosuppressive drugs within 2 weeks prior to the first dose.
• •3. Presence or history of any active autoimmune disease, including, but not limited to: autoimmune hepatitis, interstitial pneumonia, pulmonary fibrosis, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism.
• •4. Pulmonary radiation therapy \> 30 Gy within 6 months prior to first dose;
• •5. Palliative radiotherapy completed 7 days prior to first dose.
• •6. Known or symptomatic active central nervous system (CNS) metastases or carcinomatous meningitis during screening.
• •7. Clinically significant cardiovascular or cerebrovascular disease
• •\-